Source 1primary paper2025MED
Toolkit/CAR-MΦ
CAR-MΦ
Also known as: CAR-macrophage, chimeric antigen receptor-macrophages
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
chimeric antigen receptor-macrophages (CAR-MΦ)
Usefulness & Problems
Why this is useful
CAR-MΦ are engineered macrophages presented as a promising adoptive cell therapy platform for solid tumors. The abstract links them to phagocytosis, trogocytosis, cytokine secretion, and adaptive-immune cross-talk.; engineered cell therapy for solid tumors; tumor microenvironment remodeling
Source:
CAR-MΦ are engineered macrophages presented as a promising adoptive cell therapy platform for solid tumors. The abstract links them to phagocytosis, trogocytosis, cytokine secretion, and adaptive-immune cross-talk.
Source:
engineered cell therapy for solid tumors
Source:
tumor microenvironment remodeling
Problem solved
The platform is positioned as an alternative to conventional CAR-T approaches that struggle in solid tumors.; offers an alternative innate immune platform for solid tumors
Source:
The platform is positioned as an alternative to conventional CAR-T approaches that struggle in solid tumors.
Source:
offers an alternative innate immune platform for solid tumors
Problem links
offers an alternative innate immune platform for solid tumors
LiteratureThe platform is positioned as an alternative to conventional CAR-T approaches that struggle in solid tumors.
Source:
The platform is positioned as an alternative to conventional CAR-T approaches that struggle in solid tumors.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
cross-talk with adaptive immunitycytokine secretionphagocytosistrogocytosistumor-microenvironment remodelingTechniques
No technique tags yet.
Target processes
manufacturingrecombinationsignalingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
The platform requires macrophage engineering and CAR construct design, with lineage-specific signaling domains such as FcRγ highlighted in the abstract.; requires macrophage engineering; solid-tumor efficacy must contend with antigen heterogeneity and immunosuppressive TME
The abstract notes unresolved issues including transient in vivo survival, manufacturing complexity, and off-target inflammation.; transient in vivo survival; manufacturing complexity; risk of off-target inflammation
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successHuman Clinicaltherapeutic use
Inferred from claim c4 during normalization. Early-phase clinical studies such as CT-0508 demonstrate feasibility and tumor-microenvironment remodeling with CAR-MΦ. Derived from claim c4. Quoted text: Early-phase clinical studies (e.g., CT-0508) demonstrate feasibility and TME remodeling with CAR-MΦ.
Source:
Supporting Sources
Ranked Claims
Early-phase clinical studies such as CT-0508 demonstrate feasibility and tumor-microenvironment remodeling with CAR-MΦ.
Early-phase clinical studies (e.g., CT-0508) demonstrate feasibility and TME remodeling with CAR-MΦ.
CAR-NK and CAR-MΦ have emerged as promising innate immune alternatives to conventional CAR-T cells for solid tumors.
innate immune cell platforms, particularly chimeric antigen receptor-engineered natural killer (CAR-NK) cells and chimeric antigen receptor-macrophages (CAR-MΦ), have emerged as promising alternatives
Recent CAR-NK and CAR-MΦ advances include lineage-specific intracellular signaling domains, novel effector constructs, and scalable iPSC-derived platforms.
We highlight key innovations, including the use of lineage-specific intracellular signaling domains (e.g., DAP12, 2B4, FcRγ), novel effector constructs (e.g., NKG7-overexpressing CARs, TME-responsive CARs), and scalable induced pluripotent stem cell (iPSC)-derived platforms.
Dual-effector regimens, cytokine-modulated cross-support, and bispecific or logic-gated CARs may overcome current barriers and provide more durable, tumor-selective responses.
Emerging combinatorial strategies, such as dual-effector regimens (CAR-NK+ CAR-MΦ), cytokine-modulated cross-support, and bispecific or logic-gated CARs, may overcome these barriers and provide more durable, tumor-selective responses.
Persistent challenges for CAR-NK and CAR-MΦ include transient in vivo survival, manufacturing complexity, and risks of off-target inflammation.
However, persistent challenges remain, including transient in vivo survival, manufacturing complexity, and risks of off-target inflammation.
Preclinical data support enhanced antitumor activity of CAR-NK and CAR-MΦ through MHC-unrestricted cytotoxicity, phagocytosis, trogocytosis, cytokine secretion, and cross-talk with adaptive immunity.
Preclinical data support enhanced antitumor activity through mechanisms such as major histocompatibility complex (MHC)-unrestricted cytotoxicity, phagocytosis, trogocytosis, cytokine secretion, and cross-talk with adaptive immunity.
Approval Evidence
1 source5 linked approval claimsfirst-pass slug car-m
chimeric antigen receptor-macrophages (CAR-MΦ)
Source:
clinical feasibilitysupports
Early-phase clinical studies such as CT-0508 demonstrate feasibility and tumor-microenvironment remodeling with CAR-MΦ.
Early-phase clinical studies (e.g., CT-0508) demonstrate feasibility and TME remodeling with CAR-MΦ.
Source:
comparative platform positioningsupports
CAR-NK and CAR-MΦ have emerged as promising innate immune alternatives to conventional CAR-T cells for solid tumors.
innate immune cell platforms, particularly chimeric antigen receptor-engineered natural killer (CAR-NK) cells and chimeric antigen receptor-macrophages (CAR-MΦ), have emerged as promising alternatives
Source:
design innovationsupports
Recent CAR-NK and CAR-MΦ advances include lineage-specific intracellular signaling domains, novel effector constructs, and scalable iPSC-derived platforms.
We highlight key innovations, including the use of lineage-specific intracellular signaling domains (e.g., DAP12, 2B4, FcRγ), novel effector constructs (e.g., NKG7-overexpressing CARs, TME-responsive CARs), and scalable induced pluripotent stem cell (iPSC)-derived platforms.
Source:
limitationsupports
Persistent challenges for CAR-NK and CAR-MΦ include transient in vivo survival, manufacturing complexity, and risks of off-target inflammation.
However, persistent challenges remain, including transient in vivo survival, manufacturing complexity, and risks of off-target inflammation.
Source:
mechanistic activitysupports
Preclinical data support enhanced antitumor activity of CAR-NK and CAR-MΦ through MHC-unrestricted cytotoxicity, phagocytosis, trogocytosis, cytokine secretion, and cross-talk with adaptive immunity.
Preclinical data support enhanced antitumor activity through mechanisms such as major histocompatibility complex (MHC)-unrestricted cytotoxicity, phagocytosis, trogocytosis, cytokine secretion, and cross-talk with adaptive immunity.
Source:
Comparisons
Source-stated alternatives
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Source-backed strengths
associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity; early-phase clinical feasibility is noted for CT-0508
Source:
associated with phagocytosis
Source:
associated with trogocytosis
Source:
associated with cross-talk with adaptive immunity
Source:
early-phase clinical feasibility is noted for CT-0508
Compared with CAR-NK
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with CAR-NK cells
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with CAR-T
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with CAR-T cells
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with CAR-T cell therapy
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with CAR-T therapy
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with chimeric antigen receptor natural killer cells
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with chimeric antigen receptor T cells
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with Chimeric antigen receptor T-cell therapy
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Compared with logic-gated CAR designs
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Shared frame: source-stated alternative in extracted literature
Strengths here: associated with phagocytosis; associated with trogocytosis; associated with cross-talk with adaptive immunity.
Relative tradeoffs: transient in vivo survival; manufacturing complexity; risk of off-target inflammation.
Source:
The abstract discusses CAR-NK cells, conventional CAR-T cells, and emerging combinatorial or logic-gated CAR strategies as nearby alternatives or complements.
Ranked Citations
- 1.